Okay, let's tackle this question. The user wants me to create a detailed explanation for a multiple-choice question about cangrelor and ticagrelor. First, I need to recall what these drugs are. Both are antiplatelet agents, right? Cangrelor is a P2Y12 receptor antagonist, and so is ticagrelor. They're used in acute coronary syndromes to prevent platelet aggregation.

The question is asking for the feature that's not common between them. Let me think about their differences. Cangrelor is an intravenous drug, while ticagrelor is oral. That's a big difference in administration route. Also, cangrelor has a very short half-life, maybe minutes, whereas ticagrelor has a longer half-life, so it's used for longer-term therapy.

Another point: cangrelor is a reversible antagonist, but ticagrelor is also reversible? Wait, clopidogrel is irreversible, but ticagrelor and cangrelor are reversible. So that's a similarity. Both inhibit ADP-induced platelet aggregation via P2Y12 receptors.

What about onset of action? Cangrelor works immediately because it's IV, while ticagrelor takes a bit longer to take effect. Also, adverse effects: both can cause bleeding, but maybe cangrelor is more associated with certain side effects like dyspnea? Wait, ticagrelor is more likely to cause dyspnea as a side effect. Hmm.

Now, looking at the options (even though the user didn't provide them), the correct answer would be the one that's different. Since the user's correct answer is not specified, I need to infer based on typical exam questions. The most common difference is the route of administration. So if one of the options says "oral administration" or "IV administration," that's the exception.

Also, considering metabolism: cangrelor is not metabolized, just excreted, while ticagrelor is metabolized in the liver. Another difference is duration of action. Cangrelor is used for periprocedural use, like during PCI, while ticagrelor is for long-term antiplatelet therapy.

So the correct answer is likely an option that states they both are administered orally, which is false because cangrelor is IV. Alternatively, an option about duration or reversibility. But the most common exception is the route. Let me structure the explanation accordingly, making sure to highlight the core concept, why the correct answer is right, why the wrong ones aren't, and a clinical pearl.

**Core Concept**
Cangrelor and ticagrelor are both P2Y₁₂ receptor antagonists used for antiplatelet therapy. They inhibit ADP-mediated platelet aggregation but differ in pharmacokinetic profiles and clinical use. Key differences include route of administration, duration of action, and reversibility of action.

**Why the Correct Answer is Right**
The exception lies in their **route of administration**. Cangrelor is a **short-acting intravenous** agent used periprocedurally (e.g., during PCI), while ticagrelor is an **oral** agent for long-term antiplatelet therapy. Cangrelor’s rapid onset and offset make it ideal for acute settings, whereas tic

✓ Correct Answer: C. Both drugs can be given orally